Cargando…

Editorial: Exploring the Potential of PSMA-PET Imaging on Personalized Prostate Cancer Treatment

Detalles Bibliográficos
Autores principales:	Ilhan, Harun, Royce, Trevor, Qiu, Xuefeng, Zamboglou, Constantinos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847759/ https://www.ncbi.nlm.nih.gov/pubmed/35186765 http://dx.doi.org/10.3389/fonc.2022.832747

Ejemplares similares

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Editorial: Advances in radiotherapy for prostate cancer
por: Kamran, Sophia C., et al.
Publicado: (2022)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2021)

Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With De Novo Lymph Node-Positive Prostate Cancer
por: Spohn, Simon K.B., et al.
Publicado: (2022)

Intraindividual Comparison Between [(18)F] PSMA-1007 PET/CT and Multiparametric MRI for Radiotherapy Planning in Primary Prostate Cancer Patients
por: Marinescu, Ioana M., et al.
Publicado: (2022)

Targeted Prostate Biopsy Using (68)Gallium PSMA-PET/CT for Image Guidance
por: Simopoulos, Demetrios N., et al.
Publicado: (2017)

Combining (68)Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
por: Kirste, Simon, et al.
Publicado: (2021)

Comparison of Manual and Semi-Automatic [(18)F]PSMA-1007 PET Based Contouring Techniques for Intraprostatic Tumor Delineation in Patients With Primary Prostate Cancer and Validation With Histopathology as Standard of Reference
por: Spohn, Simon K. B., et al.
Publicado: (2020)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Predictive and prognostic potential of pretreatment (68)Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
por: Assadi, Majid, et al.
Publicado: (2022)

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
por: Pan, Ke-Hao, et al.
Publicado: (2021)

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer
por: Alberto, Matthew, et al.
Publicado: (2022)

Low-Dose 68 Ga-PSMA Prostate PET/MRI Imaging Using Deep Learning Based on MRI Priors
por: Deng, Fuquan, et al.
Publicado: (2022)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging
por: Topoozian, Mark, et al.
Publicado: (2023)

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative (68)Ga-PSMA-11 PET/CT
por: Qiu, Xuefeng, et al.
Publicado: (2021)

Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective
por: Ng, Thomas S. C., et al.
Publicado: (2021)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [(18)F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
por: Shenderov, Eugene, et al.
Publicado: (2017)

Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in (68)GaPSMA-11 PET images of patients with primary prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2020)

Isolated, PSMA-negative penile metastasis from castration resistant prostate adenocarcinoma, identified by FDG-PET
por: Chau, Matthew, et al.
Publicado: (2022)

PSMA PET imaging in the diagnosis and management of prostate cancer
por: Houshmand, Sina, et al.
Publicado: (2023)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

Solitary castrate-resistant prostate cancer metastasis to adrenal gland with concordant intense avidity on PSMA and FDG PET
por: McGeorge, Stephen, et al.
Publicado: (2021)

Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada
por: Young, Sympascho, et al.
Publicado: (2021)

PSMA-targeted [(18)F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework
por: Reyes, Diane K., et al.
Publicado: (2019)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

PSMA-targeted therapy for non-prostate cancers
por: Wang, Jarey H., et al.
Publicado: (2023)

Preclinical evaluation and first in human study of Al(18)F radiolabeled ODAP-urea-based PSMA targeting ligand for PET imaging of prostate cancer
por: Ren, Ya’nan, et al.
Publicado: (2022)

Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
por: Schmidt Hegemann, Nina-Sophie, et al.
Publicado: (2020)

Correlation Between Quantitative PSMA PET Parameters and Clinical Risk Factors in Non-Metastatic Primary Prostate Cancer Patients
por: Zschaeck, Sebastian, et al.
Publicado: (2022)

The (18)F-PSMA-1007 PET/CT performance on metastasis status and therapy assessment in oligo-metastasis prostate cancer
por: Wang, Zhuonan, et al.
Publicado: (2022)

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation
por: Bergamini, Marco, et al.
Publicado: (2022)

Imaging tumour thrombus of clear cell renal cell carcinoma: FDG PET or PSMA PET? Direct in vivo comparison of two technologies
por: Saadat, Seyedehpariya, et al.
Publicado: (2017)

Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer
por: Sirtl, Simon, et al.
Publicado: (2021)

(18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
por: Zhou, Shuoming, et al.
Publicado: (2022)

Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
por: Lilleby, Oscar, et al.
Publicado: (2019)

Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer
por: Zhou, Xing, et al.
Publicado: (2021)

Case Report: (18)F-PSMA PET/CT May Improve the Clinical Management of Penile Metastases From Prostate Cancer
por: Fan, Junjie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_21a5tpr0br0qvq5alionhsegms